The Pfizer Foundation is seeking proposals for a competitive program aimed at addressing key challenges in HRRm testing—whether through germline, tissue-based, or circulating tumor DNA (ctDNA) approaches—in the metastatic castration-sensitive prostate cancer (mCSPC) setting. This competitive grant program is designed to support projects that tackle practical and systemic barriers in HRRm testing and coordination within
Access Restricted: Members-Only Content. We're sorry, but this content is available exclusively to our subscribed members: